These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 3822918)
1. Role of prolactin in modulating the effects of tamoxifen on growth of the Dunning R3327 rat prostate adenocarcinoma. Sylvester PW; Ip MM Prostate; 1987; 10(1):57-67. PubMed ID: 3822918 [TBL] [Abstract][Full Text] [Related]
2. Antiestrogens do not counteract the inhibitory effect of estradiol-17 beta on the growth of the Dunning R3327 prostatic adenocarcinoma. Landström M; Damber JE; Bergh A; Tomic R; Carlsson-Bostedt L; Stigbrand T Prostate; 1988; 12(4):287-98. PubMed ID: 3393491 [TBL] [Abstract][Full Text] [Related]
3. Functionality of estrogen receptor and tamoxifen treatment of R3327 Dunning rat prostate adenocarcinoma. Ip MM; Milholland RJ; Rosen F Cancer Res; 1980 Jul; 40(7):2188-93. PubMed ID: 7388787 [TBL] [Abstract][Full Text] [Related]
4. Differential effects of prolactin on rat dorsolateral prostate and R3327 prostatic tumor sublines. Johnson MP; Thompson SA; Lubaroff DM J Urol; 1985 Jun; 133(6):1112-20. PubMed ID: 4039764 [TBL] [Abstract][Full Text] [Related]
5. Effects of 6-methylene progesterone on growth, morphology, and blood flow of the Dunning R3327 prostatic adenocarcinoma. Damber JE; Bergh A; Daehlin L; Petrow V; Landström M Prostate; 1992; 20(3):187-97. PubMed ID: 1574466 [TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of androgen-primed chemotherapy in the Dunning R3327 G model of prostatic cancer. English HF; Heitjan DF; Lancaster S; Santen RJ Cancer Res; 1991 Apr; 51(7):1760-5. PubMed ID: 2004359 [TBL] [Abstract][Full Text] [Related]
7. Estrogen treatment postpones the castration-induced dedifferentiation of Dunning R3327-PAP prostatic adenocarcinoma. Landström M; Damber JE; Bergh A Prostate; 1994 Jul; 25(1):10-8. PubMed ID: 8022707 [TBL] [Abstract][Full Text] [Related]
8. Estrogen treatment combined with castration inhibits tumor growth more effectively than castration alone in the Dunning R3327 rat prostatic adenocarcinoma. Landström M; Bergh A; Tomic R; Damber JE Prostate; 1990; 17(1):57-68. PubMed ID: 1696714 [TBL] [Abstract][Full Text] [Related]
9. Antitumoral effects of R 75251 on the growth of transplantable R3327 prostatic adenocarcinoma in rats. Van Ginckel R; De Coster R; Wouters W; Vanherck W; van der Veer R; Goeminne N; Jagers E; Van Cauteren H; Wouters L; Distelmans W Prostate; 1990; 16(4):313-23. PubMed ID: 2371176 [TBL] [Abstract][Full Text] [Related]
10. Hormonal and chemotherapeutic treatment of prostatic carcinoma; Dunning adenocarcinoma of the prostate in Copenhagen-Fischer rats. Rosenberg CA; Hrushesky WJ; Langevin T; Kennedy BJ Oncology; 1985; 42(1):48-54. PubMed ID: 3969257 [TBL] [Abstract][Full Text] [Related]
11. Dunning R3327-G prostate carcinoma of the rat: an appropriate model for drug evaluation. Kager M; Spruss T; Schneider MR; von Angerer E J Cancer Res Clin Oncol; 1992; 118(5):334-8. PubMed ID: 1583064 [TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Pinski J; Reile H; Halmos G; Groot K; Schally AV Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203 [TBL] [Abstract][Full Text] [Related]
13. Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma. Zaccheo T; Giudici D; di Salle E Prostate; 1997 Feb; 30(2):85-91. PubMed ID: 9051146 [TBL] [Abstract][Full Text] [Related]
14. Growth of Dunning transplantable prostate adenocarcinomas in rats fed diets with various fat contents. Clinton SK; Palmer SS; Spriggs CE; Visek WJ J Nutr; 1988 Jul; 118(7):908-14. PubMed ID: 3392600 [TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy in rats of CGP 19984, a thiazolidinedione derivative that inhibits luteinizing hormone secretion. Ip MM; Sylvester PW; Schenkel L Cancer Res; 1986 Apr; 46(4 Pt 1):1735-40. PubMed ID: 3948162 [TBL] [Abstract][Full Text] [Related]
16. Coordinate loss of growth regulatory factors following castration of rats carrying the Dunning R3327 G prostatic tumor. Rubenstein M; Shaw M; Targonski P; McKiel CF; Dubin A; Guinan PD Clin Physiol Biochem; 1992; 9(2):47-50. PubMed ID: 1284786 [TBL] [Abstract][Full Text] [Related]
17. An inhibitory effect of TZP-4238 on the growth of androgen-sensitive rat prostatic tumor (Dunning R3327). Ichikawa T; Akimoto S; Shimazaki J Endocr J; 1993 Aug; 40(4):425-30. PubMed ID: 7522799 [TBL] [Abstract][Full Text] [Related]
18. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model. Redding TW; Schally AV Prostate; 1985; 6(3):219-32. PubMed ID: 3157927 [TBL] [Abstract][Full Text] [Related]
19. Tumor progression in serial passages of the Dunning R3327-G rat prostatic adenocarcinoma: growth rate response to endocrine manipulation. Pollack A; Block NL; Stover BJ; Irvin GL Cancer Res; 1985 Mar; 45(3):1052-7. PubMed ID: 3971360 [TBL] [Abstract][Full Text] [Related]
20. Effect of medroxyprogesterone acetate, alone or in combination with epirubicin hydrochloride, on the growth of the Dunning R3327H prostatic adenocarcinoma. Landström M; Tomić R; Damber JE Eur Urol; 1987; 13(3):203-6. PubMed ID: 2956111 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]